

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Metacam 15 mg/ml oral suspension for pigs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

**Active substance:**

Meloxicam: 15 mg

**Excipients:**

<b>Qualitative composition of excipients and other constituents</b>	<b>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</b>
Sodium benzoate	1.5 mg
Sorbitol, liquid	
Glycerol	
Saccharin sodium	
Xylitol	
Sodium dihydrogen phosphate dihydrate	
Silica, colloidal anhydrous	
Hydroxyethylcellulose	
Citric acid	
Honey aroma	
Water, purified	

Yellowish viscous oral suspension with a green tinge.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Pigs

### **3.2 Indications for use for each target species**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (Mastitis-Metritis-Agalactia syndrome MMA) with appropriate antibiotic therapy.

### **3.3 Contraindications**

Do not use in pigs suffering from impaired hepatic, cardiac or renal function or haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### **3.4 Special warnings**

None.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species

Avoid use in very severely dehydrated, hypovolaemic or hypotensive pigs which require parenteral rehydration, as there may be a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This veterinary medicinal product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

#### Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

None.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation

Can be used during pregnancy and lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

### **3.9 Administration routes and dosage**

Oral use.

To be administered at a dosage of 0.4 mg/kg body weight (i.e. 2.7 ml/100 kg) in combination with antibiotic therapy, as appropriate. If required, a second administration of Meloxicam can be given after 24 hours.

In cases of MMA with severely disturbed general demeanour (e.g. anorexia) the use of Metacam 20 mg/ml solution for injection is recommended.

To be administered preferably mixed with a small quantity of feed. Alternatively to be given prior to feeding, or directly into the mouth.

The suspension should be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In case of overdose symptomatic treatment should be initiated.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Meat and offal: 5 days.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code:**

QM01AC06

### **4.2 Pharmacodynamics**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by intravenous *E. coli* endotoxin administration in pigs.

### **4.3 Pharmacokinetics**

#### Absorption

After a single oral dose of 0.4 mg meloxicam/kg a  $C_{max}$  value of 0.81 mcg/ml was reached after 2 hours.

#### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

#### Metabolism

Meloxicam is predominantly found in plasma. Bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

#### Elimination

After oral administration the mean plasma elimination half-life is approximately 2.3 hours. Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

None known.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening of the immediate packaging: 6 months

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **5.4 Nature and composition of immediate packaging**

Cardboard box containing one polyethylene bottle of 100 ml or 250 ml with a polyethylene tip adapter, a tamper-proof child-resistant closure and a measuring syringe. Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.  
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Boehringer Ingelheim Vetmedica GmbH

## **7. MARKETING AUTHORISATION NUMBER**

Vm 04491/5019

## **8. DATE OF FIRST AUTHORISATION**

05 July 2010

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

February 2024

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*  
Approved: 20 March 2025